Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE

Key Points

• Aurora Investment Counsel acquired 25,501 Haemonetics shares worth approximately $1.9 million in the second quarter, giving it a 0.06% stake. Institutional investors collectively own 99.67% of the company.
• Haemonetics exceeded quarterly expectations with $339.4 million in revenue and adjusted EPS of $1.14, prompting management to raise its full-year revenue-growth outlook to 5%–8%.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $95, while Barrington Research recently raised its target to $118.

Aurora Investment Counsel acquired a new stake in Haemonetics Corporation (NYSE:HAE - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,501 shares of the medical instruments supplier's stock, valued at approximately $1,913,000. Aurora Investment Counsel owned about 0.06% of Haemonetics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its stake in shares of Haemonetics by 12.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier's stock worth $108,000 after purchasing an additional 211 shares during the period. Quantinno Capital Management LP boosted its holdings in Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier's stock worth $261,000 after buying an additional 289 shares during the last quarter. UMB Bank n.a. grew its position in shares of Haemonetics by 110.9% during the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 306 shares during the period. Cardinal Capital Management grew its position in shares of Haemonetics by 1.5% during the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier's stock worth $1,799,000 after buying an additional 321 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Haemonetics in the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

HAE has been the topic of several recent analyst reports. Barrington Research lifted their price objective on shares of Haemonetics from $95.00 to $118.00 and gave the stock an "outperform" rating in a research note on Wednesday. Raymond James Financial reaffirmed an "outperform" rating and issued a $105.00 target price on shares of Haemonetics in a research note on Friday, August 7th. Robert W. Baird set a $96.00 target price on shares of Haemonetics in a report on Friday, August 7th. JPMorgan Chase & Co. lifted their price target on shares of Haemonetics from $62.00 to $86.00 and gave the stock a "neutral" rating in a research report on Friday, August 7th. Finally, Bank of America raised shares of Haemonetics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $72.00 to $80.00 in a report on Friday, May 22nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Haemonetics presently has an average rating of "Moderate Buy" and an average price target of $95.00.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: New CSL Plasma supply agreement: Haemonetics signed a non-exclusive agreement to supply CSL Plasma’s U.S. collection operations. The deal restores business with a major customer after a prior supply transition weighed on results, potentially improving revenue visibility and supporting the company’s plasma-collection franchise. Haemonetics reconnects with CSL in US plasma collection deal
• Positive Sentiment: Raised fiscal 2027 outlook and solid quarterly results: Haemonetics reported quarterly revenue of $339.4 million, up approximately 5.6% year over year, while adjusted EPS rose to $1.14 and exceeded consensus. Management raised its full-year reported revenue-growth forecast to 5%–8% from 4%–7%, with plasma revenue and adoption of Persona PLUS on the NexSys PCS platform providing momentum. Haemonetics Jumps as Investors Cheer Raised Fiscal 2027 Outlook
• Positive Sentiment: Analyst support: BTIG raised its price target from $96 to $110 and maintained a Buy rating, reinforcing bullish momentum. BTIG raises Haemonetics price target

Haemonetics Trading Up 3.6%

HAE opened at $108.39 on Thursday. The stock has a market capitalization of $4.93 billion, a P/E ratio of 53.14, a P/E/G ratio of 2.10 and a beta of 0.52. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $108.50. The firm's fifty day simple moving average is $80.50 and its 200 day simple moving average is $67.90. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.06. The firm had revenue of $339.38 million during the quarter, compared to analysts' expectations of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The company's revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.10 EPS. As a group, research analysts anticipate that Haemonetics Corporation will post 5.28 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source